Nanosphere, Inc.

Nanosphere develops, manufactures and markets an advanced molecular diagnostic platform, the Verigene System, which enables simple, cost-effective, and highly sensitive nucleic acid (DNA and RNA) and protein testing on a single platform.

Our breakthrough technology helps hospitals improve patient care and lowers costs by providing time-critical information, allowing earlier detection of disease and more targeted treatment. Our products have the potential to:

Empower physicians to better manage infectious diseases through timely and clinically actionable diagnostic information; Enable earlier detection of life-threatening disease through ultra sensitive protein tests, while advancing the viability and clinical significance of new and existing biomarkers; Improve patient outcomes and reduce medical costs through point-of-care pharmacogenetic tests.

The Verigene System is differentiated by its ease of use, rapid turnaround times and ability to detect many targets on a single test, referred to as multiplexing. We are developing, completing clinical trials, and commercializing a broad menu of tests.